Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome

Lancet

Volumn 349, Issue 9053, 1997, Pages 697-698

  Brensing, K A ^a   Textor, J ^a   Strunk, H ^a   Klehr, H U ^a   Schild, H ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL;

EID: 0031035980     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)24010-9     Document Type: Article

References (5)

1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
2. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991; 51: 428-30.
3. Lake JR, Ring E, LaBerge J, et al. Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 1993; 25: 1766-67.
4. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
5. Wong F, Sniderman K, Liu P, et al. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern M ed 1995; 122: 816-22.